Cite
HARVARD Citation
Meyer, T. et al. (2017). Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet gastroenterology and hepatology. pp. 565-575. [Online].